biomedicina slovenica


pr=Brodowicz : 12

  1. Casali P. G.; Abecassis N.; Biagini R.; Bielack Stefan; Bonvalot S.; Boukovinas I.; Bovée Judith VMG; Brodowicz Thomas; Frezza A. M.; Unk Mojca
    Gastrointestinal stromal tumours
    2022
  2. Gronchi A.; Abecassis N.; Biagini R.; Bielack Stefan; Bonvalot S.; Boukovinas I.; Bovée Judith VMG; Brodowicz Thomas; Casali P. G.; Unk Mojca
    Soft tissue and visceral sarcomas
    2021
  3. Casali P. G.; Abecassis N.; Biagini R.; Bielack Stefan; Bonvalot S.; Boukovinas I.; Bovée Judith VMG; Brodowicz Thomas; Broto J. M.; Unk Mojca
    Soft tissue and visceral sarcomas
    2018
  4. Casali P. G.; Abecassis N.; Biagini R.; Bielack Stefan; Bonvalot S.; Boukovinas I.; Bovée Judith VMG; Brodowicz Thomas; Broto J. M.; Unk Mojca
    Gastrointestinal stromal tumours
    2018
  5. Thallinger Christiane; Lang Istvan; Grašič-Kuhar Cvetka; Bartsch Rupert; Singer Christian F.; Petruželka Luboš; Melichar Bohuslav; Knittelfelder Regina; Brodowicz Thomas; Zielinski Christoph C.
    Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer
    2016
  6. Ciuleanu Tudor; Scheithauer W.; Kurteva G.; Ocvirk Janja; Koza I.; Papamichael D.; Wenczl M.; Brodowicz Thomas; Beslija Semir; Zielinski Christoph C.
    A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    2008
  7. Anghel Rodica; Bachmann Alexander; Beksac Meral; Brodowicz Thomas; Finek Jindřich; Komadina Radko; Krzemieniecki Krzysztof; Lang Istvan; Marencak Jozef; Moos Roger von; Pecherstorfer Martin; Rordorf Tamara; Vrbanec Damir; Zielinski Christoph C.
    Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
    2013
  8. Modest Dominik P.; Brodowicz Thomas; Stintzing Sebastian; Jung Andreas; Neumann Jens; Laubender R. P.; Ocvirk Janja; Kurteva G.; Papai Z.; Knittelfelder R.; Kirchner Thomas; Heinemann V.; Zielinski Christoph C.
    Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy
    2012
  9. Peterson P.; Zwitter Matjaž; Krzakowski Maciej; Wenczl M.; Tzekova V.; Ramlau R.; Ciuleanu T.; Liepa A.; Zielinski C.; Brodowicz Thomas
    Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy
    2006
  10. Krzakowski M; Wenczl M; Brodowicz T; Tzekova V; Ramlau R; Ghilezan N; Čučević B; Ulsperger E; Zielinski M; Zwitter M
    Gemcitabine and cisplatin (GC) +/- subsequent theapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European cooperative
    2004
  11. Krzakowski Maciej; Wenczl Miklos; Brodowicz Thomas; Tzekova Valentina; Ramlau Rodryg; Ghilezan Nicolae; Cucevic Branka; Gyurkovits Kalman; Zwitter Matjaž
    Gemcitabine and cisplatin (GC)+/- subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European cooperative oncology group (CECOG)
    2003
  12. Brodowicz T; Beslija S; Červek J; Mršič-Krmpotič Z; Tchernozemsky I; Wiltschke C; Ghilezan N; Grgič M; Jassem J; Zielinski C
    Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluoro-uracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European cooperative oncology group (CECOG)
    2001


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics